|
[1]
|
International Agency for Research on Cancer - World Health Organization. ANCER TOMORROW. A tool that predicts the future cancer incidence and mortality burden worldwide from the current estimates in 2020 up until 2040 Lyon, France 2020. http://gco.iarc.fr/tomorrow/home. [2021-10-28].http://gco.iarc.fr/tomorrow/home |
|
[2]
|
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317(23):2402 − 16. http://dx.doi.org/10.1001/jama.2017.7112CrossRef
|
|
[3]
|
Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 2020;38(7):674 − 85. http://dx.doi.org/10.1200/JCO.19.01907CrossRef
|
|
[4]
|
Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 2019;37(6):453-60. http://dx.doi.org/10.1200/JCO.18.01631. |
|
[5]
|
Norum J, Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Undlien DE, et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO Open 2018;3(3):e000328. http://dx.doi.org/10.1136/esmoopen-2018-000328CrossRef
|
|
[6]
|
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22(6):1055 − 62. http://dx.doi.org/10.1200/JCO.2004.04.188CrossRef
|
|
[7]
|
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827 − 34. http://dx.doi.org/10.1016/S0140-6736(13)60140-3CrossRef
|
|
[8]
|
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101(2):80 − 7. http://dx.doi.org/10.1093/jnci/djn442CrossRef
|
|
[9]
|
Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of ‘premenopausal risk-reducing salpingo-oophorectomy’ for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet 2016;53(9):591 − 9. http://dx.doi.org/10.1136/jmedgenet-2016-103800CrossRef
|
|
[10]
|
Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol 2019;5(12):1718 − 30. http://dx.doi.org/10.1001/jamaoncol.2019.3323CrossRef
|
|
[11]
|
Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Consensus guidelines on genetic` testing for hereditary breast cancer from the American society of breast surgeons. Ann Surg Oncol 2019;26(10):3025 − 31. http://dx.doi.org/10.1245/s10434-019-07549-8CrossRef
|
|
[12]
|
Balmaña J, Sanz J, Bonfill X, Casado A, Rué M, Gich I, et al. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer 2004;112(4):647 − 52. http://dx.doi.org/10.1002/ijc.20458CrossRef
|
|
[13]
|
Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 2010;28(4):675 − 82. http://dx.doi.org/10.1200/JCO.2008.21.4684CrossRef
|
|
[14]
|
Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 2019;121(1):15 − 21. http://dx.doi.org/10.1038/s41416-019-0446-1CrossRef
|
|
[15]
|
Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol 2014;15(7):e279 − 89. http://dx.doi.org/10.1016/S1470-2045(13)70567-9CrossRef
|
|
[16]
|
Sun L, Cui B, Wei X, Sadique Z, Yang L, Manchanda R, et al. Cost-effectiveness of genetic testing for all women diagnosed with breast cancer in China. Cancers (Basel) 2022;14(7):1839. http://dx.doi.org/10.3390/cancers14071839CrossRef
|